Nhà máy Stada
Cardiovascular Agents

Trimetazidin STADA® 20 mg


Pack size:

Box of 2 blisters x 30 film-coated tablets.



Each film-coated tablet contains trimetazidine dihydrochloride 20 mg.



24 months from the date of manufacturing.

Store in a well-closed container, in a dry place.

Protect from light. Do not store above 30oC.


  • Indications and Dosage & Administration
  • Contraindications
  • Adverse reactions
  • Precautions

  • Indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.
  • Usual dose: One tablet, three times a day during meals.
  • Patients with moderate renal impairment (creatinine clearance [30-60] ml/min):
    The recommended dose is one tablet, twice daily, one in the morning and one in the evening during meals.
    Elderly patients may have increased trimetazidine exposure due to age-related decrease in renal function. In patients with moderate renal impairment (creatinine clearance [30-60] ml/min), the recommended dose is one tablet, twice daily, one in the morning and one in the evening during meals.
    Dose titration in elderly patients should be exercised with caution.
    The safety and efficacy of trimetazidine in children aged below 18 years have not been established. No data are available.

Or as prescribed by physicians.


  • Hypersensitivity to the active substance or to any ingredient of the drug.
  • Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders.
  • Severe renal impairment (creatinine clearance < 30 ml/min).



  •  Dizziness, headache.
  •  Abdominal pain, diarrhoea, dyspepsia, nausea and vomiting.
  •  Asthenia.
  •  Rash, pruritus, urticaria.


  • Palpitations, extrasystoles, tachycardia. Arterial hypotension, orthostatic hypotension that may be associated with malaise, dizziness or fall, in particular in patients taking antihypertensive treatment, flushing.

Not known

  •  Parkinsonian symptoms (tremor, akinesia, hypertonia), gait instability, restless leg syndrome, other related movement disorders, usually reversible after treatment discontinuation.
  •  Sleep disorders (insomnia, drowsiness).
  •  Constipation.
  •  Acute generalized exanthematus pustulosis, angioedema.
  •  Agranulocytosis thrombocytopenia, thrombocytopenic purpura.
  • Hepatitis.


  • Trimetazidine can cause or worsen parkinsonian symptoms (tremor, akinesia, hypertonia), which should be regularly investigated, especially in elderly patients. In doubtful cases, patients should be referred to a neurologist for appropriate investigations.
  • The occurrence of movement disorders such as parkinsonian symptoms, restless leg syndrome, tremors, gait instability should lead to definitive withdrawal of trimetazidine.
  • These cases have a low incidence and are usually reversible after treatment discontinuation. The majority of the patients recovered within 4 months after trimetazidine withdrawal. If parkinsonian symptoms persist more than 4 months after drug discontinuation, a neurologist opinion should be sought.
  • Falls may occur, related to gait instability or hypotension, in particular in patients taking antihypertensive treatment.
  • Caution should be exercised when prescribing trimetazidine to patients in whom an increased exposure is expected:
  • Moderate renal impairment.
  • Elderly patients older than 75 years old.
  • Trimetazidine should not be prescribed to pregnancy and nursing women.
  • Trimetazidine may cause symptoms, such as dizziness and drowsiness which may affect ability to drive and use machines.


Contact us

FACTORY 1: K63/1 Nguyen Thi Soc St., Xuan Thoi Dong, Hoc Mon, HCMC
Tel: +84 28 3718 2141 - Fax: +84 28 3718 2140

FACTORY 2: 40 Tu Do Avenue, VietNam-Singapore Industrial Park, Binh Duong
Tel: +84 274 376 7470 - Fax: +84 274 376 7469
Email : stada@stada.com.vn
Website: www.stada.com.vn

Visitors Counter